A Phase 2 interventional study of Photobiomodulation - INTRAORAL and Photobiomodulation - EXTRAORAL in Oral Mucositis, sponsored by Brigham and Women's Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2025-12-18.
Sponsored by Brigham and Women's Hospital · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Stomatitis with a site in United States — 12 open to participants now, 15 under way, none of them phase 3. Stomatitis · United States.
Among the 80 studies in Stomatitis with a site in United States, this one is the 29th largest by planned enrollment of the 73 interventional ones that give a count, is one of 2 that started in 2025, is one of 33 in phase 2, reaches primary completion later than 3 of the 14 other live ones, and was the 75th registered.
307 studies on the registry are indexed under Stomatitis; 74 are open to participants now.
Browse Stomatitis studies →12 of the 80 studies in Stomatitis with a site in United States are open now. Recruiting first, the newest first:
UNCANCER LLC · Sites in United States
Ages 18+
Baptist Health South Florida · Sites in United States
Ages 18+
AstraZeneca · Sites in United States
Ages 18+
Woman's · Sites in United States
Ages 18+
NRG Oncology · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 45 Stomatitis studies recruiting now, 20 (44%) set no upper age limit and 21 (47%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.
This study: 4 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 35 · Phase 3 9 · Phase 4 4
First in 1999; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 78 is above the median of 60 across 277 interventional studies indexed under Stomatitis.
Median enrollment 60 across the 73 interventional studies, 22 across the 6 observational. Of the 60 that completed or were terminated, 26 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 80 have an industry lead sponsor. The 10 most frequent:
Brigham and Women's Hospital is the lead sponsor of 1,270 studies on the registry; 230 are open to participants now.
Of its 117 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.
Brigham and Women's Hospital has 1 study filed under Stomatitis — fewer than ten, so there is no comparison to draw.
8 of the studies in Stomatitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07290413Brigham and Women's HospitalPhotobiomodulation for the Prevention of Oral Mucositis | 2026-12 |
| NCT04805320University of NebraskaAssociation of Periodontal Inflammation on Immune Response in Wound Healing | 2027-01 |
| NCT06532279NRG OncologyTesting the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer | 2027-01-01 |
| NCT07287826Woman'sUsing a Steroid Mouthwash to Prevent Mouth Sores During Chemotherapy | 2027-07 |
| NCT05966194EpicentRx, Inc.RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer | 2027-07-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 80 studies in Stomatitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if photobiomodulation works to prevent severe oral mucositis in patients who are undergoing allogeneic hematopoietic cell transplantation. The main questions it aims to answer are:
Does 1) intraoral , 2) extraoral, or 3) combined intraoral/extraoral photobiomodulation have optimal prevention/therapeutic effect in prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation (alloHSCT).
Participants will:
Be randomized to one of the three treatment arms Receive daily photobiomodulation therapy (from beginning of transplant conditioning through Day +20 after transplantation) Be evaluated for oral mucositis and symptoms daily Visit the clinic once every 2 weeks for checkups and tests Keep a diary of their symptoms and the number of times they use a rescue inhaler
Patients who are planned for alloHSCT will be randomized 1:1:1 to one of the 3 treatment arms, stratified by age (\<18, ≥ 18years). This is a phase 2 randomized trial to identify which of the three photobiomodulation therapy (PBMT) devices, 1) intraoral , 2) extraoral, and 3) combined intraoral/extraoral, has optimal prevention/therapeutic effect in prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation (alloHSCT). The study will be conducted in parallel, in a quasi-multi-center manner at three other alloHSCT centers (AC Camargo, SP, Brazil; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Cincinnati Children's Hospital Medical Center; in addition to DFCI/BWH).
Participants will be evaluated daily according to the validated WHO Oral Toxicity Scale by trained and calibrated investigators. Within each arm, a Simon's 2 stage design will be applied in an intention to treat analysis of the proportion of patients who have \<5 days of WHO grade ≥ 3 OM, to eliminate arms with insufficient evidence of efficacy. The remaining arms will be analyzed in a selection design (pick the winner) to determine the probability that the arm selected for a future phase 3 trial is either superior to, or at worst, more or less equivalent to, other arm(s). The study will enroll up to 96 patients with up to 26 patients per treatment arm. The accrual rate at DFCI is anticipated to be 2 patients/month, or 24 patients per year. The same accrual rate is anticipated at each of the other three study sites. Therefore, the total accrual of 78 patients can be achieved within 1 year.
The primary endpoint, duration of severe OM, is defined in section 11.1 as the total number of days between day 0 and day +20 on which severe (WHO grade 3 or 4) OM was reported. A conservative approach to missing data will be taken: Any day on which the grading of mucositis is missing will be counted as a day with WHO grade ≥3 OM. Each patient will be classified as either a success or a failure. "Success" will be defined as a patient who has a duration of WHO grade ≥3 OM \<5 days; a patient with ≥5 days will be classified as a "failure" (i.e., a binary endpoint).
The secondary endpoints that will be subjectively considered in making the final selection of the winning arm are:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intraoral PBMT device: The THOR intraoral PBMT device emits LED light with an irradiance of 50 mW/cm2 and, when applied for 60 seconds, delivers 3 J/cm2. It is a handheld device with an array of LEDs covered by smooth glass. The therapeutic area is small enough (similar to a popsicle) to place in the mouth comfortably.
Device: Photobiomodulation - INTRAORAL
Extraoral PBMT device: The extraoral PBMT device is a dual headed probe designed to be connected to the LX2.3 Laser and LED Therapy System. It consists of two high-powered probes designed to emit 850nm light at an intensity of 240 m/cm2. The device is dual-headed in order to treat both sides of the head simultaneously without the need for a sperate control unit.
Device: Photobiomodulation - EXTRAORAL
Participants in this arm will receive both intraoral and extraoral photobiomodulation.
Device: Photobiomodulation - INTRAORAL and EXTRAORAL
Participants will receive intraoral photobiomodulation
Participants will receive extraoral photobiomodulation
Participants will receive intraoral and extraoral photobiomodulation
Duration of severe oral mucositis according to the World Health Organization Oral Toxicity Score
WHO Score (0-4, "severe" defined as grades 3 and 4)
Time frame: Oral mucositis is assessed daily from day 0 through day +20
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
Of 39 phase 2 interventional studies under Stomatitis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brigham and Women's Hospital →